Analysis of the effect of SARS-CoV-2 vaccination in patients with chronic inflammatory diseases
Suspended
- Conditions
- Healthy controls SARS-CoV-2 vaccinatedchronic inflammation
- Registration Number
- DRKS00024214
- Lead Sponsor
- KSH Kiel/1. medizinische Klinik/Rheumatologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
a SARS-CoV-2 vaccination is planned. In addition, one of the following diseases: standard criteria (ACR/EULAR) for diagnosed Rheumatoid arthritis, spondyloarthorpathy, vasculitis or collagenosis. Gastroenterological diagnosed chronic inflammatory bowel disease (Morbus Crohn or Colitis Ulcerosa), Dermatologically confirmed Psoriasis.
For the control group, the mentioned diseases are exclusion criteria.
In addition, written informed consent is needed.
Exclusion Criteria
maligne disease, other autoimmune diseases (with immunosuppressive therapy), Infections (e.g. HIV, Hep C, Hep B) Age under 18 years, lacking capacity to consent.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Antibodies against SARS-CoV-2 can be measured 1 week after the second immunisation.
- Secondary Outcome Measures
Name Time Method Antibodies against SARS-CoV-2 can be measured 6 months after the second immunisation.